Gilead Sciences (LIM:GILD) Other Long Term Assets : $6,479 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Gilead Sciences Other Long Term Assets?

Gilead Sciences's other long-term assets for the quarter that ended in Mar. 2024 was $6,479 Mil.

Gilead Sciences's quarterly other long-term assets increased from Sep. 2023 ($4,200 Mil) to Dec. 2023 ($4,792 Mil) and increased from Dec. 2023 ($4,792 Mil) to Mar. 2024 ($6,479 Mil).

Gilead Sciences's annual other long-term assets declined from Dec. 2021 ($4,963 Mil) to Dec. 2022 ($4,801 Mil) and declined from Dec. 2022 ($4,801 Mil) to Dec. 2023 ($4,792 Mil).

Gilead Sciences Other Long Term Assets Historical Data

The historical data trend for Gilead Sciences's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Other Long Term Assets Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

7,438.00

5,708.00

4,963.00

4,801.00

4,792.00

Gilead Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long Term Assets	Get a 7-Day Free Trial															4,952.00	5,113.00	4,200.00	4,792.00	6,479.00

Gilead Sciences Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Gilead Sciences (LIM:GILD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LIM:GILD) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.